<?xml version='1.0' encoding='utf-8'?>
<document id="26947173"><sentence text="The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study."><entity charOffset="83-91" id="DDI-PubMed.26947173.s1.e0" text="Warfarin" /></sentence><sentence text="Roxadustat is a small-molecule hypoxia-inducible factor prolyl-hydroxylase inhibitor in late-stage clinical development for the treatment of anemia in patients with chronic kidney disease (CKD)" /><sentence text=" Warfarin is an oral anticoagulant with a narrow therapeutic window that is often prescribed to treat coexisting cardiovascular diseases in patients with CKD"><entity charOffset="1-9" id="DDI-PubMed.26947173.s3.e0" text="Warfarin" /></sentence><sentence text=" This clinical trial was designed to evaluate the effect of roxadustat on warfarin pharmacokinetic and pharmacodynamic parameters"><entity charOffset="60-70" id="DDI-PubMed.26947173.s4.e0" text="roxadustat" /></sentence><sentence text="" /><sentence text="This open-label, single-sequence crossover study was conducted in healthy volunteers (male or female) aged 18 to 55 years with a body mass index of 18" /><sentence text="5 to 30" /><sentence text="0 kg/m(2)" /><sentence text=" The study consisted of 2 periods separated by a minimum washout period of 14 days" /><sentence text=" After an overnight fast, volunteers received a single oral dose of 25 mg (5 × 5 mg tablets) warfarin on Day 1 of Period 1 and Day 7 of Period 2" /><sentence text=" Volunteers received oral doses of 200 mg (2 × 100 mg tablets) roxadustat on Days 1, 3, 5, 7 (concomitant with warfarin), 9, 11, 13, and 15 of Period 2"><entity charOffset="63-73" id="DDI-PubMed.26947173.s11.e0" text="roxadustat" /></sentence><sentence text=" Plasma S- and R-warfarin (unbound and total concentrations) and prothrombin time were determined at multiple time points up to 216 hours postdose" /><sentence text=" Pharmacokinetic and pharmacodynamic parameters were estimated via noncompartmental methods" /><sentence text=" Tolerability was evaluated by monitoring adverse events, laboratory assays, vital signs, and 12-lead ECGs" /><sentence text="" /><sentence text="The geometric mean ratios and 90% CIs for Cmax and AUC∞ of total and unbound S- and R-warfarin (with and without roxadustat) were within the standard bioequivalence interval of 80"><entity charOffset="84-94" id="DDI-PubMed.26947173.s16.e0" text="R-warfarin" /><entity charOffset="113-123" id="DDI-PubMed.26947173.s16.e1" text="roxadustat" /><pair ddi="false" e1="DDI-PubMed.26947173.s16.e0" e2="DDI-PubMed.26947173.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26947173.s16.e0" e2="DDI-PubMed.26947173.s16.e1" /></sentence><sentence text="00% to 125" /><sentence text="00%" /><sentence text=" Roxadustat increased the geometric mean (GM) prothrombin (PT) and international normalized ratio (INR) AUC from time zero to last measurable sample (AUCPT,last and AUCINR,last) by 24" /><sentence text="4%" /><sentence text=" Coadministration of roxadustat and warfarin in healthy volunteers was associated with a favorable tolerability profile, with most treatment-associated adverse events mild in severity"><entity charOffset="21-31" id="DDI-PubMed.26947173.s21.e0" text="roxadustat" /></sentence><sentence text="" /><sentence text="Based on the lack of clinically significant pharmacokinetic interactions and the limited influence on warfarin pharmacodynamic parameters, no dose adjustment of warfarin should be required when coadministered with roxadustat"><entity charOffset="214-224" id="DDI-PubMed.26947173.s23.e0" text="roxadustat" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT02252731" /><sentence text="" /></document>